[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)]. 1981

M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007948 Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES. Leukemia, Monoblastic, Acute,Leukemia, Myeloid, Acute, M5,Leukemia, Myeloid, Schilling-Type,Monoblastic Leukemia, Acute,Monocytic Leukemia, Acute,Myeloid Leukemia, Acute, M5,Myeloid Leukemia, Schilling-Type,Leukemia, Acute Monocytic,Leukemia, Myeloid, Schilling Type,Acute Monoblastic Leukemia,Acute Monoblastic Leukemias,Acute Monocytic Leukemia,Acute Monocytic Leukemias,Leukemia, Schilling-Type Myeloid,Leukemias, Acute Monoblastic,Leukemias, Acute Monocytic,Monoblastic Leukemias, Acute,Monocytic Leukemias, Acute,Myeloid Leukemia, Schilling Type,Schilling-Type Myeloid Leukemia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009279 Naphthacenes Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Tetracenes,Benz(b)Anthracenes
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
February 1985, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
July 1981, [Rinsho ketsueki] The Japanese journal of clinical hematology,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
September 1986, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
October 1985, Cancer,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
July 1989, European journal of haematology,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
July 1983, Cancer research,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
October 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
January 1989, Advances in experimental medicine and biology,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
December 1990, Cancer research,
M Hirano, and Y Morishita, and T Ino, and T Matsui, and S Shimizu, and H Shigemura, and K Nakamura, and Y Ono, and M Saito
January 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Copied contents to your clipboard!